Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

Autor: Mikkel G. Terp, Odd L. Gammelgaard, Henriette Vever, Morten F. Gjerstorff, Henrik J. Ditzel

Publikováno v: Molecular Oncology, Vol 15, Iss 12, Pp 3299-3316 (2021)

RAS‐MAPK signaling promotes immune evasion and cancer cell survival, and MAPK inhibitors (MAPKis) are frequently used as cancer therapies. Despite progress elucidating the direct effects of MAPKi on immune cells, their indirect effect on the tumor

Externí odkaz: https://doaj.org/article/f3d6962653184d478d74f58cf2f92dc3

Human cancer evolution in the context of a human immune system in mice

Autor: Odd L. Gammelgaard, Mikkel G. Terp, Birgitte Preiss, Henrik J. Ditzel

Publikováno v: Molecular Oncology, Vol 12, Iss 10, Pp 1797-1810 (2018)

Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer ce

Externí odkaz: https://doaj.org/article/65d3998ca8fe41e9845f10ffcec098f5

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

Autor: Morten F. Gjerstorff, Henrik J. Ditzel, Mikkel G. Terp, Henriette Vever, Odd L. Gammelgaard

Publikováno v: Molecular Oncology, Vol 15, Iss 12, Pp 3299-3316 (2021)
Molecular Oncology
Terp, M G, Gammelgaard, O L, Vever, H, Gjerstorff, M F & Ditzel, H J 2021, ' Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer : combined targeting could improve outcomes ', Molecular Oncology, vol. 15, no. 12, pp. 3299-3316 . https://doi.org/10.1002/1878-0261.13046

RAS‐MAPK signaling promotes immune evasion and cancer cell survival, and MAPK inhibitors (MAPKis) are frequently used as cancer therapies. Despite progress elucidating the direct effects of MAPKi on immune cells, their indirect effect on the tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d6b0a6dd7f34b8be4340bccc1db439
https://doaj.org/article/f3d6962653184d478d74f58cf2f92dc3

Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity

Autor: Odd L Gammelgaard, Mikkel G Terp, Christian Renn, Aran F Labrijn, Oliver Hamaker, Aaraby Y Nielsen, Henriette Vever, Soren WK Hansen, Morten F Gjerstorff, Christa E Müller, Paul WHI Parren, Henrik J Ditzel

Publikováno v: Journal for ImmunoTherapy of Cancer, 10(9). BMJ PUBLISHING GROUP

BackgroundImmunosuppressive extracellular adenosine is generated by the enzymatic activity of CD73. In preclinical models, antibodies (Abs) targeting different epitopes on CD73 exert anticancer activity through distinct mechanisms such as inhibition

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae93beea27221f5e2380b2fabc47370
https://pubmed.ncbi.nlm.nih.gov/36096528

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Autor: Ana Bosch, Mikkel G. Terp, Henrik J. Ditzel, Monique F. Hundebøl, Neil Portman, Lene E. Johansen, Kamila Kaminska, Gabriella Honeth, Carla Maria Lourenco Alves, Martin Bak, Odd L. Gammelgaard, Elgene Lim, Martina Tuttolomondo, Sidse Ehmsen

Publikováno v: Nature Communications
Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ', Nature Communications, vol. 12, 5112 . https://doi.org/10.1038/s41467-021-25422-9
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)

CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most patients will eventually experience disease progression on this combination, underscoring t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909c54d06c561d241308a49e7f7f6e84
https://pubmed.ncbi.nlm.nih.gov/34531405